Abstract 2370
Background
Male breast cancer is a rare disease that have different outcomes in comparison with the same disease in female counterparts. Due to rarity of its occurrence, data available on breast cancer in male population are relatively scarce. The aim of this study was to summarize data available in the SEER (National Cancer Institute Surveillance, Epidemiology, and End Results) program’s database about male breast cancer. SEER incorporates data from 18 cancer registries all over the United States. Data about clinical and epidemiological patterns as well as survival were analyzed and are subsequently presented.
Methods
Data were obtained using SEER*Stat version 8.3.5 where (SEER 18 Regs Nov 2017 Submission) database was used as the data source. Only males diagnosed between 2000-2015 with malignant breast cancer, known age, and microscopic confirmation were included. Relative survival was calculated using Ederer II method. Further data analysis was made using SPSS version 21.
Results
A total of 6790 patients were identified with a median age of 68. White race constituted the majority of cases (81.3%; n = 5519). Incidence rate was 10.2 per million (95% CI 10 – 10.5) with increasing trend over time (annual percent change = 1.9%, p < 0.05). The disease showed slight predilection to occur on the left side (52.3%; n = 3550). Most cases were staged as regional (n = 2974) or localized (n = 3152) at time of diagnosis. The disease was the only primary cancer in 4502 patients (66.3%) and the first of 2 or more primaries in 787 cases (11.6%). It occurred as a second or later multiple primary in remaining cases (22.1%). Median observed survival was 117.2 months with a 5-years and 10-years observed survival of 70.6% (CI: 69.1%-71.9%) and 48.8% (CI: 46.9%-50.6%) respectively. 5-years relative survival was 84% (CI: 82.3%-85.6%) while 10-years relative survival was 71.1% (CI: 68.3%-73.7%).
Conclusions
Male breast cancer is a rare tumor with an incidence rate of 10.2 per million. This tumor is more likely to occur in old age and white race and occurs more on left side. Disease occurred as a second (or later multiple) primary in 22% of cases. 5-years relative survival is 84% with a median survival of 117.2 months.
Clinical trial identification
Legal entity responsible for the study
Mohamed Alaa Gouda.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract